TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34610874
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention (PCI) with second-generation drug-eluting stents (DES) in patients without left main involvement
Study: 34610923
Drug: Dihydrotestosterone (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrotestosterone (median 0.9 nmol/L)
Study: 34610923
Drug: Testosterone (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (median 12.1 nmol/L)
Study: 34611045
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy (APT), including aspirin and other antiplatelet drugs, administered to 730 patients (9% of total), with 680 receiving single APT and 50 receiving dual APT.
Study: 34611164
Drug: Subunit PfEMP1
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subunit PfEMP1 (VAR2CSA) vaccine
Study: 34611424
Drug: D-CTAG regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-CTAG regimen (decitabine, cytarabine, aclarubicin) with rhTPO and G-CSF
Study: 34613416
Drug: Telavancin 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telavancin 5 mg/kg IV administered 3 hours before haemodialysis
Study: 34613416
Drug: Telavancin 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telavancin 5 mg/kg IV administered post-haemodialysis
Study: 34613570
Drug: OBP-801 (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBP-801 (1.0 mg/m²)
Study: 34613570
Drug: OBP-801 (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBP-801 (2.0 mg/m²)
Study: 34613570
Drug: OBP-801 (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBP-801 (3.0 mg/m²)
Study: 34614506
Drug: Venetoclax (200-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (200-400 mg daily starting day -8 for 6-7 doses) plus fludarabine (30 mg/m2 per day for 4 doses) and busulfan (0.8 mg/kg twice daily for 8 doses on day -5 to day -2)
Study: 34615718
Drug: BMS-986148 monotherapy
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-986148 monotherapy (0.1-1.6 mg/kg i.v. every 3 weeks)
Study: 34615718
Drug: BMS-986148 once-weekly
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BMS-986148 once-weekly monotherapy (0.4 or 0.6 mg/kg i.v.)
Study: 34615723
Drug: Buparlisib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib (100 mg) and Ibrutinib (560 mg)
Study: 34615725
Drug: Ivuxolimab (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivuxolimab (0.3 to 10 mg/kg)
Study: 34616296
Drug: Bevacizumab as
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab as first-line treatment
Study: 34616588
Drug: Camrelizumab combined
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab combined with concurrent chemotherapy (cisplatin 25 mg/m2) and radiation therapy
Study: 34616588
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy (cisplatin 25 mg/m2) and radiation therapy
Study: 34618197
Drug: Single 3-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 3-mg dose of PF-06881894
Study: 34618197
Drug: Single 6-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 6-mg dose of PF-06881894
Study: 34618197
Drug: Multiple 6-mg
Normalized name: CHEMSTRIP 6 (MULTIPLE) TEST STRIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple 6-mg doses of PF-06881894
Study: 34618197
Drug: PF-06881894 (3-
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06881894 (3- or 6-mg doses)
Study: 34618498
Drug: Digital messaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital messaging intervention (0-6 messages daily for 6 months)
Study: 34619098
Drug: BNT162b2 (tozinameran,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 (tozinameran, Pfizer-BioNTech) vaccine
Study: 34619104
Drug: Benralizumab 30
Normalized name: benralizumab 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab 30 mg (subcutaneous injection) every 4 weeks for three doses, then every 8 weeks thereafter.
Study: 34620022
Drug: Acetyl-DL-leucine (ADLL)
Normalized name: N-Acetyl-DL-Tryptophan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-DL-leucine (ADLL) 3 g/day for 1 week followed by 5 g/day for 3 weeks to 1 year
Study: 34620081
Drug: Gym Tonic
Normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gym Tonic (GT) programme (12 weeks, twice/week)
Study: 34620167
Drug: Budesonide/glycopyrrolate/formoterol fumarate
Normalized name: budesonide/glycopyrrolate/formoterol fumarate 160 mcg-9 mcg-4.8 mcg/actuation INHALATION HFA AEROSOL WITH ADAPTER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) 160/9/4.8 μg per actuation, 2 actuations, radiolabeled with technetium-99-pertechnetate.
Study: 34620167
Drug: Budesonide/glycopyrrolate/formoterol fumarate
Normalized name: budesonide/glycopyrrolate/formoterol fumarate 160 mcg-9 mcg-4.8 mcg/actuation INHALATION HFA AEROSOL WITH ADAPTER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) 320/18/9.6 μg, radiolabeled.
Study: 34620226
Drug: Cultivated oral
Normalized name: Cultivated mushroom
DrugBank: Cultivated mushroom (DB10544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cultivated oral mucosal epithelial cell sheets (COMET)
Study: 34620226
Drug: Cultivated oral
Normalized name: Cultivated mushroom
DrugBank: Cultivated mushroom (DB10544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cultivated oral mucosal epithelial cell sheets (COMET) followed by corneal transplantation
Study: 34620335
Drug: Early enteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early enteral or oral nutrition (EEN/ON)
Study: 34620666
Drug: Antibiotic stewardship
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic stewardship intervention (ASI) using a decision tool and educational materials.
Study: 34620702
Drug: Ipilimumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (3 mg/kg every 3 weeks for four treatments)
Study: 34620785
Drug: Systane iLux
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systane iLux thermal pulsation treatment
Study: 34621707
Drug: YH4808 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH4808 100 mg twice a day
Study: 34621707
Drug: YH4808 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH4808 200 mg once a day
Study: 34621707
Drug: YH4808 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH4808 200 mg twice a day
Study: 34623313
Drug: Inhaled iloprost
Normalized name: iloprost Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled iloprost via Breelib nebulizer
Study: 34623637
Drug: Modafinil 400
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil 400 mg once daily for 14 days
Study: 34623695
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection therapy
Study: 34624252
Drug: Camrelizumab 200
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab 200 mg every 2 weeks plus apatinib 250 mg once per day
Study: 34625791
Drug: Daratumumab combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab combined with all-trans retinoic acid (ATRA) at a dose of 45 mg/m2
Study: 34626024
Drug: RM-1929 photoimmunotherapy
Normalized name: morphine sulfate Rectal Suppository [RMS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: RM-1929 photoimmunotherapy (640 mg/m)
Study: 34626797
Drug: ART-I02, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART-I02, a recombinant adeno-associated virus (AAV) serotype 5 vector expressing interferon (IFN)-β, administered as a single intra-articular (IA) injection, dosage not fully specified but mentioned as 0.3 × 10 and 0.6 × 10.
Study: 34627332
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg once daily)
Study: 34627340
Drug: Baricitinib (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib (4 mg for patients aged ≥6 to <18 years and 2 mg for patients <6 years)
Study: 34627340
Drug: Adalimumab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (20 mg for patients weighing <30 kg and 40 mg for patients ≥30 kg)
Study: 34627593
Drug: Intralesional TTI-621
Normalized name: TTI-101
DrugBank: TTI-101 (DB17578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional TTI-621 (10 mg thrice weekly for 2 weeks)
Study: 34629131
Drug: Dronabinol (synthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol (synthetic tetrahydrocannabinol [THC]), titrated to a dose of 10 mg daily
Study: 34629400
Drug: Cell-based and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell-based and gene-based therapies using iPSCs
Study: 34629400
Drug: Neuroprotection and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroprotection and drug screening opportunities
Study: 34629893
Drug: Iota-Carrageenan nasal
Normalized name: iota-Carrageenan
DrugBank: iota-Carrageenan (DB15304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iota-Carrageenan nasal spray (4 daily doses for 21 days)
Study: 34629893
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray (4 daily doses for 21 days)
Study: 34630406
Drug: High-throughput, systems
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-throughput, systems serology approach to profile biophysical and functional characteristics of antibodies targeting antigens.
Study: 34631535
Drug: Primary tumour
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary tumour radiotherapy after targeted therapy
Study: 34631809
Drug: Proton Pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton Pump Inhibitors (PPIs) co-administered with Dual Antiplatelet Therapy
Study: 34631809
Drug: Dual Antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual Antiplatelet Therapy alone
Study: 34632935
Drug: Venetoclax monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax monotherapy (400 mg once daily) for ≤2 years
Study: 34633084
Drug: Cenobamate (12.5-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate (12.5-200 mg/day during titration, up to 400 mg/day during maintenance)
Study: 34633084
Drug: Cenobamate (12.5-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate (12.5-25 mg/day)
Study: 34633084
Drug: Cenobamate (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate (50-100 mg/day)
Study: 34633084
Drug: Cenobamate (treatment-emergent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate (treatment-emergent adverse events)
Study: 34633152
Drug: 600-mg ziritaxestat
Normalized name: Ziritaxestat
DrugBank: Ziritaxestat (DB15403)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600-mg ziritaxestat (oral administration)
Study: 34633152
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of ziritaxestat
Study: 34633154
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g (1 tube) of BF-200 ALA applied on the face (MUsT-1)
Study: 34633154
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g (3 tubes) of BF-200 ALA applied on the face/scalp or body periphery (MUsT-2)
Study: 34633450
Drug: 2-hour plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-hour plasma glucose (2hPG) after a 75-g oral glucose challenge
Study: 34634438
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) delivered to the whole breast to 45 to 50 Gy in standard daily fractions of 1.8 to 2.0 Gy, with a mandatory boost of 10 to 16 Gy in 2.0-Gy daily fractions to each tumor bed.
Study: 34634754
Drug: Weekly electronic
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly electronic PRO symptom monitoring for 12 months
Study: 34635048
Drug: DINOSAUR (DINO
Approvals — FDA: no, EMA: no, PMDA: no
Description: DINOSAUR (DINO Strategies for Anxiety and Intolerance of Uncertainty Reduction), a 12-week group telehealth treatment
Study: 34635128
Drug: Ultra-low tidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low tidal ventilation (4 mL/kg)
Study: 34635537
Drug: Immunosuppression reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppression reduction combined with a third BNT162b2 vaccine dose
Study: 34635537
Drug: Third BNT162b2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third BNT162b2 vaccine dose alone
Study: 34636226
Drug: Intraoperative infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative infusion of esmolol
Study: 34637072
Drug: IDegAsp treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDegAsp treatment initiated at physicians' discretion
Study: 34637337
Drug: mammalian target
Normalized name: Mammalian target of rapamycin (mTOR) kinase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: mammalian target of rapamycin inhibitor
Study: 34637506
Drug: Monthly growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly growth measurement between 9 and 11 months
Study: 34638136
Drug: Zanubrutinib, 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanubrutinib, 160 mg, twice-daily oral administration until disease progression or unacceptable toxicity
Study: 34638225
Drug: Bevacizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (15 mg/kg every 3 weeks for up to 15 months) combined with standard carboplatin-paclitaxel
Study: 34638225
Drug: Bevacizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (15 mg/kg every 3 weeks for up to 15 months)
Study: 34638369
Drug: Neoadjuvant ado-trastuzumab
Normalized name: ADO-TRASTUZUMAB
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Neoadjuvant ado-trastuzumab emtansine (T-DM1) ± endocrine therapy
Study: 34641820
Drug: Nutritional supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplementation and/or treatment of parasitic infections
Study: 34643541
Drug: Daily supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supportive text messaging for 6 months
Study: 34643541
Drug: Daily supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supportive email messaging for 6 months
Study: 34643690
Drug: MS-MRD relapse
Normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS-MRD relapse during maintenance treatment
Study: 34644145
Drug: MR-guided focused
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR-guided focused ultrasound (MRgFUS) combined with intravenous trastuzumab-based therapies
Study: 34644385
Drug: Antilymphoma treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antilymphoma treatment including anti-CD20 containing regimens
Study: 34644605
Drug: Consolidative hematopoietic
Normalized name: human cord blood hematopoietic progenitor cell
DrugBank: Human cord blood hematopoietic progenitor cell (DB11054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidative hematopoietic cell transplantation (HCT) after CD19 CAR T cell therapy
Study: 34644605
Drug: Consolidative HCT
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Consolidative HCT after CAR T cell therapy
Study: 34644735
Drug: hu3S193 antibody
Normalized name: hu3S193
DrugBank: hu3S193 (DB17213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hu3S193 antibody administration at weekly intravenous doses of 20 mg/m2 for 8-week cycles
Study: 34645390
Drug: Machine Learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine Learning (ML) analysis of ECG patterns
Study: 34645390
Drug: ML algorithm
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML algorithm testing
Study: 34645514
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of blue dye and a radioactive isotope in the stumps of the ligamentum ovarium proprium and the ligamentum infundibulo-pelvicum.
Study: 34645514
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of tracer in the ovarian ligaments before tumor resection.
Study: 34645648
Drug: Adavosertib (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adavosertib (225 mg twice daily on days 1-3, 8-10, and 15-17) plus carboplatin every 21 days
Study: 34645648
Drug: Adavosertib (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adavosertib (various dosages) combined with chemotherapy agents (gemcitabine, paclitaxel, carboplatin, pegylated liposomal doxorubicin)
Study: 34646440
Drug: Adjunct low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunct low-dose aripiprazole (5 mg) added to current antipsychotic for 12 weeks
Study: 34647988
Drug: Mobocertinib 160
Normalized name: Mobocertinib
DrugBank: Mobocertinib (DB16390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mobocertinib 160 mg once daily
Study: 34648147
Drug: Psoriasis Treatment
Normalized name: MG217 Psoriasis
DrugBank: Sophora flavescens root (DB14565)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psoriasis Treatment Convenience Scale (PTCS)
Study: 34649279
Drug: Ofatumumab (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofatumumab (1000 mg IV on days 0 and 14) and prednisone (1 mg/kg/day)
Study: 34649276
Drug: Ponatinib 45
Normalized name: PONATinib 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib 45 mg/d for 48 weeks plus prednisone tapered to 60 mg/m2/d from days -14 to 29; prophylactic intrathecal chemotherapy administered monthly.
Study: 34649784
Drug: Dietary app-supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary app-supported tele-counseling intervention (8 weeks duration, weekly dietitian tele-counseling)
Study: 34649873
Drug: VY-AADC01 (AAV2
Approvals — FDA: no, EMA: no, PMDA: no
Description: VY-AADC01 (AAV2 gene therapy) delivered via bilateral, intraoperative MRI-guided putaminal infusions.
Study: 34650930
Drug: Bevacizumab combined
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab combined with corticosteroids (5 mg/kg, two to four cycles)
Study: 34651137
Drug: Enteral dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral dextrose infusion (50% dextrose; 0.5 g/mL) at 10 mL per hour for 24 hours
Study: 34651222
Drug: Enerisant hydrochloride
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enerisant hydrochloride (5 mg)
Study: 34651222
Drug: Enerisant hydrochloride
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enerisant hydrochloride (12.5 mg)
Study: 34651222
Drug: Enerisant hydrochloride
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enerisant hydrochloride (25 mg)
Study: 34653210
Drug: Subcutaneous immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunoglobulin (SCIG) with Hizentra every 7±2 days for 24 weeks
Study: 34653210
Drug: Subcutaneous immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunoglobulin (SCIG) with Hizentra
Study: 34653242
Drug: Ruxolitinib 20
Normalized name: ruxolitinib 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 20 mg PO twice daily until progression
Study: 34653252
Drug: Crinecerfont 100
Normalized name: crinecerfont 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crinecerfont 100 mg twice daily for 14 days
Study: 34653252
Drug: Crinecerfont 100
Normalized name: crinecerfont 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crinecerfont 100 mg once daily at bedtime for 14 days
Study: 34653252
Drug: Crinecerfont 100
Normalized name: crinecerfont 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crinecerfont 100 mg once daily in the evening for 14 days
Study: 34653252
Drug: Crinecerfont 50
Normalized name: crinecerfont 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crinecerfont 50 mg once daily at bedtime for 14 days
Study: 34653525
Drug: Standard drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drug treatments without LD-RT
Study: 34654283
Drug: Pharmaceutical recommendations
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical recommendations by clinical pharmacists
Study: 34654283
Drug: Diuretic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic therapy recommendations
Study: 34654464
Drug: Individual Placement
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual Placement and Support (IPS) plus treatment as usual (TAU)
Study: 34655570
Drug: EGCG solution
Normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG solution
Study: 34655570
Drug: EGCG solution
Normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG solution with casein addition
Study: 34655683
Drug: Baseline AAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline AAA volume, tortuosity, MTD, current tobacco use, angiotensin II receptor blocker use, and history of diabetes mellitus
Study: 34656148
Drug: Dose reduction
Normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reduction (DR) of IL-17 and IL-23 inhibitors, with dosing intervals prolonged stepwise to achieve 66% and 50% of the original dose.
Study: 34656173
Drug: Internet-based occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based occupational therapy intervention 'Strategies for Empowering activities in Everyday life' (SEE, version 1.0)